

London, 17 September 2009  
Doc. Ref.: EMEA/HMPC/102303/2008

## COMMITTEE ON HERBAL MEDICINAL PRODUCT (HMPC)

### DRAFT

#### LIST OF REFERENCES FOR ASSESSMENT OF

**Cimicifugae rhizoma**  
**Cimicifuga racemosa (L.) Nutt., rhizoma**  
**(black cohosh)**

*The EMEA acknowledges that copies of the underlying works used to produce this monograph were provided for research only with exclusion of any commercial purpose.*

#### I) References cited in the Assessment Report

Amato P, Christophe S, Mellon PL. Estrogenic activity of herbs commonly used as remedies for menopausal symptoms. Menopause 2002, 9(2): 145-150

Amato P, Marcus DM. Review of alternative therapies for treatment of menopausal symptoms. Climacteric 2003, 6: 278-284

Antoine C, Liebens F, Carly B, Pastijn A, Rozenberg S. Safety of alternative treatments for menopausal symptoms after breast cancer: a qualitative systemic review. Climacteric 2007, 10: 23-26

Bai W, Henneicke-von Zepelin HH, Wang S, Zheng S, Liu J, Zhang Z et al. Efficacy and tolerability of a medicinal product containing an isopropanolic black cohosh extract in Chinese women with menopausal symptoms: a randomized, double blind, parallel-controlled study versus tibolone. Maturitas 2007, 58: 31-41

Bartsch HH, Fischer J et al. AWB mit Remifemin bei Mamma-Ca-Patientinnen mit klimakterischen Beschwerden unter Tamoxifen: Integrierter medizinischer und biometrischer Bericht, Schaper & Brümmer Data published in Thesis: Juliane Fischer: Cimicifuga racemosa Extrakt (Remifemin®) bei Mamma-Ca-Patientinnen mit klimakterischen Beschwerden unter hormontherapeutischer Behandlung mit Tamoxifen – eine Anwendungsbeobachtung. Albert-Ludwigs-Universität Freiburg i.Br. 2006

Becher H, Henneicke-von Zepelin HH, Schröder-Bernhardi D, Stammwitz U. Pharmakoepidemiologische Kohortenstudie zur Anwendung von Remifemin® / Remifemin®Plus bei Patientinnen mit Mammakarzinom einschließlich Hormonrezeptor positiver Tumoren. J. Menopause 2/2005 Abstract Kongress der DGM

Beuscher N. *Cimicifuga racemosa* L.- Die Traubensilberkerze, Portrait einer Arzneipflanze, Z Phytotherapie 1995, 5: 301-310

Boekhout AH, Beijnen JH, Schellens JHM. Symptoms and treatment in cancer therapy-induced early menopause. *The Oncologist* 2006, 11: 641-654

Briese V, Stammwitz U, Friede M, Henneicke-von Zepelin HH. Black cohosh with or without St. John's wort for symptom-specific climacteric treatment – results of a large-scale, controlled, observational study. *Maturitas* 2007, 57: 405-414

Bruno D, Feeney KJ. Management of postmenopausal symptoms in breast cancer survivors. *Seminars in Oncology*. ELSEVIER 2006, 33: 696-707

Carpenter J. State of the science: hot flashes and cancer. Part 2: Management and future directions. *Oncology nursing forum* 2005, 32(5): 969-78

Chlebowski RT, Kim JA, Col NF. Estrogen deficiency symptom management in breast cancer survivors in the changing context of menopausal hormone therapy. *Seminars in Oncology*. December 2003, 30(6): 776-788

Commission E (Germany), Monographie: *Cimicifugae racemosae rhizoma* (*Cimicifugawurzelstock*), BAnz Nr. 43, 02.03.1989

Daiber W. Klimakterische Beschwerden: ohne Hormone zum Erfolg, Ärztliche Praxis, Die Zeitung des Arztes in Klinik und Praxis, Sonderdruck; XXXV. Jahrgang Nr. 65 1983, 1946-1947

Davis VL, Jayo MJ, Hardy ML, Ho A, Lee H, Shaikh F et al. Effects of black cohosh on mammary tumor development and progression in MMTV-neu transgenic mice. *Proceedings of the AACR* 2003, Vol. 44. Abstract 910

Davis VL, Jayo MJ, Ho A, Kotlarczyk MP, Hardy ML, Foster WG et al. Black cohosh increases metastatic mammary cancer in transgenic mice expressing c-erbB2. *Cancer Research* 2008, 68(20): 8377 – 8383

Dixon-Shanies D, Shaikh N. Growth inhibition of human breast cancer cells by herbs and phytoestrogens. *Oncology Reports* 1999, 6: 1383-1387

Dugoua JJ, Seely D, Perri D, Koren G, Mills E. Safety and efficacy of black cohosh (*Cimicifuga racemosa*) during pregnancy and lactation. *Can J Clin Pharmacol* 2006, 13(3): 257-261

Einbond LS, Shimizu M, Nuntanakorn P, Seter C, Cheng R, Jiang B et al. Actein and a fraction of black cohosh potentiate antiproliferative effects of chemotherapy agents on human breast cancer cells. *Planta Med* 2006, 72: 1200-1206

Einer-Jensen N, Zhao J, Andersen KP, Kristoffersen K. *Cimicifuga* and *Melbosia* lack oestrogenic effects in mice and rats. *Maturitas* 1996, 25: 149-153

EMEA. Guideline on clinical investigation of medicinal products for hormone replacement therapy of oestrogen deficiency symptoms in postmenopausal women. EMEA/CHMP/021/97 Rev. 1, London 13 October 2005

EMEA, HMPC. Guideline on the assessment of clinical safety and efficacy in the preparation of community herbal monographs for the well-established and of community herbal monographs / entries to the community list for traditional herbal medicinal products / substances / preparations, EMEA/HMPC/104613/2005, London 7 September 2006

Frei-Kleiner S, Schaffner W, Rahlfss VW, Bodmer C, Birkhäuser M. *Cimicifuga racemosa* dried ethanolic extract in menopausal disorders: a double-blind placebo-controlled clinical trial. *Maturitas* 2005, 51: 397-404

Freudenstein J, Bodinet C. Influence of an isopropanolic aqueous extract of *Cimicifugae racemosae* rhizoma on the proliferation of MCF-7 cells. In: Proceedings of the Twenty-third International LOF-Symposium of Phyto-estrogens. Ghent 1999

Freudenstein J, Dasenbrock C, Nißlein T. Lack of promotion of estrogen-dependent mammary gland tumors in vivo by an isopropanolic *Cimicifuga racemosae* extract. *Cancer Research* 2002, 62: 3448-3452

Georgiev DB, Iordanova E. Phytoestrogens – the alternative approach. *Maturitas* 1997, 27(1): 123 (abstract P309)

Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Khan IA et al. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. *Clinical Pharmacology & Therapeutics* 2005, 77(5): 415-426

Gurley BJ, Barone GW, Williams DK, Carrier J, Breen P, Yates CR, Song PF et al. Effect of milk thistle (*Silybum marianum*) and black cohosh (*Cimicifuga racemosa*) supplementation on digoxin pharmacokinetics in humans. *Drug Metabolism and disposition: the biological fate of chemicals* 2006, 34(1): 69-74

Gurley B, Hubbard MA, Williams DK, Thaden J, Tong Y, Gentry WB et al. Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a Milk Thistle and Black Cohosh product to Rifampin and Clarithromycin. *Journal of Clinical Pharmacology* 2006, 46: 201-213

Hagers Enzyklopädie. *Cimicifuga*. Springer Medizin Verlag, Heidelberg. 6. Auflage 2007, 644-661

Heinemann K, Ruebig A, Potthoff P, Schneider HPG, Heinemann LAJ, Thai DM. The Menopause Rating Scale (MRS) scale: A methodological review. *Health and Quality of Life Outcomes* 2004, 2:45

Henneicke-von Zepelin HH, Meden H, Kostev K, Schröder-Bernhardt D, Stammwitz U, Becher H. Isopropanolic black cohosh extract and recurrence-free survival after breast cancer. *International Journal of Clinical Pharmacology and Therapeutics* 2007, 45(3): 143-154

Hickey M, Saunders CM, Stuckey BGA. Management of menopausal symptoms in patients with breast cancer: an evidence-based approach. *Lancet Oncol* 2005, 6: 687-695

Hillmann E. Final report on the mutagenicity testing *Salmonella/Microsome Test (Ames Test)*. Project No.: 95-92-1189-90, 1990

Hirschberg AL, Henneicke-von Zepelin HH, Liske E, Friede M. Clinical study of the drug safety of black cohosh on breast epithelial cell proliferation and mammographic breast density in postmenopausal women. *Abstracts of free communications* 0174, 2005

Jacobson JS, Troxel AB, Evans J, Klaus L, Vahdat L, Kinne D et al. Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. *Journal of Clinical Oncology* 2001, 19(10): 2739-2745

Jarry H, Harnischfeger G, Düker E. Untersuchungen zur endokrinen Wirksamkeit von Inhaltsstoffen aus *Cimicifuga racemosa*, 2. In vitro-Bindung von Inhaltsstoffen an Östrogenrezeptoren. *Planta Medica* 1985, No. 4, August

Jarry H, Harnischfeger G. Untersuchungen zur endokrinen Wirksamkeit von Inhaltsstoffen aus *Cimicifuga racemosa*, 1. Einfluß auf die Serumspiegel von Hypophysentumoren ovariektomierter Ratten. *Planta Medica* 1985, No. 4, August

Kenemans P. Climacteric and postmenopause: definitions, terms and concepts.  
<http://www.womanlab.com/english/professionals/menopausalIssues1.htm>

Korn WD. 6-month oral toxicity study with “Remifemin-Granulate” in rats followed by an 8-week recovery period. IBR Project No.: 20-04-0913-90, 1991

Kupperman HS, Blatt MHG, Wiesbader H, Filler W. Comparative clinical evaluation of estrogenic preparations by the menopausal and amenorrheal indices. J Clin Endocrinol 1953, 13: 688-703

Lehmann-Willenbrock E, Riedel HH. Klinische und endokrinologische Untersuchungen zur Therapie ovarieller Ausfallserscheinungen nach Hysterektomie unter Belassung der Adnexe. Zent. bl. Gynäkol. 1988, 110: 611-618

Liske E, Boblitz N, Henneicke-von Zepelin HH. Therapie klimakterischer Beschwerden mit Cimicifuga racemosa – Daten zur Wirkung und Wirksamkeit aus einer randomisierten kontrollierten Doppelblindstudie. In: Rietbrock, ed, Phytopharmaka VI Forschung und klinische Anwendung. Steinkopff, Darmstadt 2000, 247-257

Liu ZP, Yu B, Huo JS, Lu CQ, Chen JS. Estrogenic effects of Cimicifuga racemosa (Black cohosh) in mice and on estrogen receptors in MCF-7 cells. J Med Food 2001, 4 (3): 171-178

Löhning AM. Beitrag zur pharmakologischen Charakterisierung von Zubereitungen aus Cimicifuga racemosa Nutt., Ranunculaceae, NSD Thesis, Westfälische Wilhelms-Universität Münster 1999

Look RM, Morris KT, Homer L, Arnold K, Purdy C, Walts D. Randomized controlled trial of Venlafaxine versus Black cohosh as a treatment for menopausal symptoms in women with breast cancer, 2001 ASCO Annual Meeting. Abstract 2973

Lüde S, Török M, Dieterle S, Knapp AC, Kaeufeler R, Jäggi R et al. Hepatic effects of Cimicifuga racemosa extract in vivo and in vitro, Cell Mol Life Sci. DOI 10.1007/s00018-007-7368-4, Birkhäuser Verlag, Basel 2007, 1-10

Mahady GB, Low Dog T, Barrett ML, Chavez ML, Gardiner P, Ko R, Marles RJ, et al. United States Pharmacopeia review of the black cohosh case reports of hepatotoxicity. Menopause 2008, 15(4): 628-638

Meyer S, Vogt T, Obermann EC, Landthaler M, Karrer S. Cutaneous pseudolymphoma induced by Cimicifuga racemosa. Dermatology 2007, 214: 94-96

Mielnik J. Extracts of Cimicifuga racemosa in the treatment of neurovegetative symptoms in women in the perimenopausal period. Maturitas 1997, 27: 215

Minciullo PL, Saija A, Patafi M, Marotta G, Ferlazzo B, Gangemi S. Muscle damage induced by black cohosh (Cimicifuga racemosa). Phytomedicine 2006, 13: 115-118

Moyad M. Complementary/alternative therapies for reducing hot flashes in prostate cancer patients: reevaluating the existing indirect data from studies of breast cancer and postmenopausal women. Urology 2002, 59(4A): 20-33

Munoz GH, Pluchino S. Cimicifuga racemosa for the treatment of hot flushes in women surviving breast cancer. Maturitas 2003, 44 (1): 59-65

Nappi R, Malavasi B, Brundu B, Facchinetto F. Efficacy of Cimicifuga racemosa on climacteric complaints: a randomized study versus low-dose transdermal estradiol. Gynecological Endocrinology. 2005, 20(1): 30-35

Nesselhut T, Liske E, (Neßelhut). Non-interventional study 1999 Remifemin®. Scientific brochure 1999 Remifemin, 26-27

Neßelhut T, Schellhase C, Dietrich R, Kuhn W. Untersuchungen zur proliferativen Potenz von Phytopharmaka mit östrogenähnlicher Wirkung bei Mammakarzinomzellen, Abstract des Vortrages von Dr. Nesselhut 8.9.92, Kongreß der Deutschen Gesellschaft für Gynäkologie, Berlin, Archives of Gynecology and Obstetrics 1993, 254: 817-818

Newton KM, Reed SD, LaCroix AZ, Grothaus LC, Ehrlich K, Guiltinan J. Treatment of Vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy or placebo. Annals of Internal Medicine 2006, 145: 869-879

Nißelein T, Freudenstein J. Concomitant administration of an isopropanolic extract of black cohosh and tamoxifen in the in vivo tumor model of implanted RUCA-I rat endometrial adenocarcinoma cells. Toxicology Letters 2004, 150: 271-275

Oktem (Öktem) M, Eroglu D, Karahan HB, Taskintuna N Kuscu, Zeyneloglu HB. Black cohosh and Fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized trial. Advances in Therapy 2007, 24(2): 448-61

Osmers R, Friede M, Liske E, Schnitker J, Freudenstein J, Henneicke-von Zepelin HH. Efficacy and safety of isopropanolic black cohosh extract for climacteric symptoms. Obstetrics & Gynecology 2005, 105 (No. 5): Part 1, May 2005 1074-1083

Palacio C, Masri G, Mooradian AD. Black cohosh for the management of menopausal symptoms; A systematic review of clinical trials. Drugs aging 2009, 26(1): 23-36

Patel NM, Derkits RM. Possible increase in liver enzymes secondary to Atorvastatin and black cohosh administration. Journal of Pharmacy Practice 2007, 20(4): 341-346

Pethö A. Umstellung einer Hormonbehandlung auf ein pflanzliches Gynäkologikum möglich?, Ärztliche Praxis, Die Zeitung des Arztes in Klinik und Praxis; Sonderdruck XXXIX. Jahrgang Nr. 47 (Seiten 1551-1553) vom 13. Juni 1987

Piersen CE. Phytoestrogens in botanical dietary supplements: implications for cancer. Integrative Cancer Therapies 2003, 2(2): 120-138

Pockaj BA, Gallagher JG, Loprinzi CL, Stella PJ, Barton DL, Sloan JA et al. Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG Trial N01CC. Journal of Clinical Oncology 2006, 24(18): 2836-2841

Pockaj BA, Loprinzi CL, Sloan JA, Novotny PJ, Barton DL, Hagenmaier A et al. Pilot evaluation of black cohosh for the treatment of hot flashes in women. Cancer Investigation 2004, 22(4): 515-521

Raus K, Brucker C, Gorkow C, Wuttke W. First-time proof of endometrial safety of the special black cohosh extract (Actaea or Cimicifuga racemosa extract) CR BNO 1055. Menopause 2006, 13(4): 678-691

Rebeck TR, Troxel AB, Norman S, Bunin GR, DeMichele A, Baumgarten M et al. A retrospective case-control study of the use of hormone-related supplements and association with breast cancer. International Journal of Cancer 2007, 120(7): 1523-1528

Rockwell S, Liu Y, Higgins SA. Alteration of the effects of cancer therapy agents on breast cancer cells by the herbal medicine black cohosh. Breast Cancer Research and Treatment 2005, 90: 233-239

Ruhlen RL, Haubner J, Tracy JK, Zhu W, Ehya H, Lamberson WR et al. Black cohosh does not exert an estrogenic effect on the breast. Nutrition and cancer 2007, 59(2): 269-277

Sakurai N, Kozuka M, Tokuda H, Nobukuni Y, Takayasu J, Nishino H et al. Antitumor agents 220. Antitumor-promoting effects of Cimigenol and related compounds on Epstein-Barr virus activation and two-stage mouse skin carcinogenesis. *Bioorganic & Medicinal Chemistry* 2003, 11: 1137-1140

Schoultz von B, Henneicke-von Zepelin HH, Liske E, Friede M, Hirschberg A. Klinische Studie zur Arzneimittelsicherheit von Remifemin® hinsichtlich Brustepithelzell-Proliferation und mammographischer Brustgewebsdichte bei postmenopausalen Frauen. Kongress der Deutschen Menopause Gesellschaft 2005; 17. und 18. Juni 2005, Münster

Simpson B. Hot flash pharmacotherapy in breast cancer survivors: a literature review. *CPJ/RPC* 2004, 137(3): 36-45

Spangler L, Newton KM, Grothaus LC, Reed SD, Ehrlich K, LaCroix AZ. The effects of black cohosh therapies on lipids, fibrinogen, glucose and insulin. *Maturitas* 2007, 57: 195-204

Stoll W. Phytotherapeutikum beeinflusst atrophisches Vaginalepithel, tpk therapeutikon Sonderdruck Heft 1 1987, 2-15

Stolze H. Der andere Weg, klimakterische Beschwerden zu behandeln, Gyne, Fachzeitung für praktische Frauenheilkunde und allgemeine Medizin 1/82; Sonderdruck Januar 1982

Vorberg G, Therapie klimakterischer Beschwerden, ZFA, Zeitschrift für Allgemeinmedizin, 60. Jahrgang Heft 13, S. 626-629, 10. Mai 1984

Walji R, Boon H, Guns E, Oneschuk D, Younus J. Black cohosh (*Cimicifuga racemosa* [L.] Nutt.): safety and efficacy for cancer patients. *Support Care Cancer* 2007, 15: 913-921

Warnecke G. Beeinflussung klimakterischer Beschwerden durch ein Phytotherapeutikum. *Med Welt* 1985, 36: 871-4

Wuttke W, Gorkow C, Seidlova-Wuttke D. Effects of black cohosh (*Cimicifuga racemosa*) on bone turnover, vaginal mucosa, and various blood parameters in postmenopausal women: a double-blind, placebo-controlled, and conjugated estrogens-controlled study. *Menopause* 2006, 13(2): 185-196

Wuttke W, Seidlova-Wuttke D, Gorkow C. The *Cimicifuga* preparation BNO 1055 vs. conjugated estrogens in a double-blind placebo-controlled study: effects on menopause symptoms and bone markers. *Maturitas* 2003, 44(1): 67-77

Zava DT, Dollbaum CM, Blen M. Estrogen and progestin bioactivity of foods, herbs, and spices. *P.S.E.B.M.* 1998, 217: 369-378

## **II) References read but not included in the Assessment Report**

Al-Amier H, Nasr KA, Lück L, Craker LE. Chemotype variation among black cohosh populations. HortScience 2005, 40(4): 1032-1033

Albertazzi P. Non estrogenic approaches for the treatment of climacteric symptoms. Climacteric 2007, 10(2): 115-120

Bland J. Position on black cohosh safety. Metagenics, Inc. September 2, 2003

Boblitz N, Liske E, Wüstenberg P. Traubensilberkerze: Wirksamkeit, Wirkung und Sicherheit von Cimicifuga racemosa in der Gynäkologie. Deutsche Apothekerzeitung 2000, 24: 107-114

Bordeleau L, Pritchard K, Goodwin P, Loprinzi C. Therapeutic options for the management of hot flashes in breast cancer survivors: an evidence-based review. Clinical Therapeutics 2007, 29(2): 230-41

Borrelli F, Ernst E. Black cohosh (Cimicifuga racemosa): a systematic review of adverse events. American Journal of Obstetrics & Gynecology 2008, 455-466

Borrelli F, Izzo AA, Ernst E. Pharmacological effects of Cimicifuga racemosa. Life science 2003, 73: 1215-1229

Brewer D, Nashelsky J, Hansen LB. Clinical inquiries. What nonhormonal therapies are effective for postmenopausal vasomotor symptoms? The journal of family practice 2003, 52 (4): 324-5, 329

Briese V, Stammwitz U, Friede M, Henneicke-von Zepelin HH. Wechseljahrestherapie ohne Hormone; Ergebnisse einer aktuellen Anwendungsbeobachtung, Kongress der Deutschen Menopause Gesellschaft 2005; 17. und 18. Juni 2005, Münster – Freie Vorträge und Poster

Burckhardt P. Selective Estrogen Receptor Modulators (SERM): neue Substanzen für die Hormonersatztherapie. Schweiz Med Wochenschr 1999, 129: 1926-30

Burdette JE, Liu J, Chen S-N, Fabricant DS, Piersen CE, Barker EL et al. Black cohosh acts as a mixed competitive ligand and partial agonist of the serotonin receptor. Journal of Agricultural and Food Chemistry 2003, 51: 5661-5670

Carroll DG. Nonhormonal therapies for hot flashes in menopause. American family physician 2006, 73(3): 457-464

Cheema D, Coomarasamy A, El-Toukhy T. Non-hormonal therapy of post-menopausal vasomotor symptoms: a structured evidence-based review. Archives of gynecology and obstetrics 2007, 276: 463-469

Chow EC-Y, Teo M, Ring JA, Chen JW. Live failure associated with the use of black cohosh for menopausal symptoms. MJA 2008, 118(7): 420-422

Cohen SM, O'Connor AM, Hart J, Merel NH, Te HS. Autoimmune hepatitis associated with the use of black cohosh: a case study. Menopause 2004, 11(5): 575-577

Doyle BJ, Mahady GB. Phytoendicines for menopause. Drugs of the future 2007, 32(10): 897-905

EMEA HMPC. Assessment of case reports connected to herbal medicinal products containing Cimicifugae racemosae rhizoma (Black cohosh, root), EMEA/HMPC/269258/2006 Rev. 1. London, 8 May 2007

EMEA. EMEA public statement on recent publications regarding hormone replacement therapy. EMEA/33065/03. London, 3 December 2003

ESCOP Monographs 2<sup>nd</sup> edition. *Cimicifugae rhizoma – Black cohosh.* European Scientific Cooperative on Phytotherapy, editor. Thieme, Stuttgart 2003, 79-91

FDA. Guidance for Industry Estrogen and Estrogen/Progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms – recommendations for clinical evaluation.

Available at:

<http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/WomensHealthResearch/UCM133343.pdf>

DRAFT. Center for drug evaluation and research US department of health and human services Food and Drug Administration Clinical/Medical January 2003

Fitzpatrick LA. Selective estrogen receptor modulators and phytoestrogens: new therapies for the postmenopausal woman. Mayo Clin Proc. 1999, 74: 601-607

Fremppong W, Kiuru A, Ericsson J, Farah M. *Cimicifuga racemosa L. Nutt.* (Black cohosh) and anaphylactic reactions, including face and oral oedema. The Uppsala Monitoring Centre

Gaube F, Wolf S, Pusch L, Kroll TC, Hamburger M. Gene expression profiling reveals effects of *Cimicifuga racemosa* (L.) NUTT. (black cohosh) on the estrogen receptor positive human breast cancer cell line MCF-7. BMC Pharmacology 2007, 7:11

Geller SE. Botanical and dietary supplements for menopausal symptoms: what works, what doesn't. J Womens Health (Larchmt) 2005, 14(7): 634-649

Geller SE, Studee L. Contemporary alternatives to plant estrogens for menopause. Maturitas 2006, 55(1): 3-13

Geller SE, Studee L. Botanical and dietary supplements for mood and anxiety in menopausal women. Menopause 2007, 14(3): 541-549

Gori L, Firenzuoli F. Is black cohosh a hepatotoxic medicinal herb? Forschende Komplementär-medizin 2007, 17: 109-110

Guideline. Abklärung von postmenopausalen Blutungen (PMPB). Schweizerische Ärztezeitung, September 2002, Version 2 2002; 83(Nr 45):

Hager, *Cimicifugae racemosae rhizoma, Chronische Toxizität,* Hagers Enzyklopädie, 6. Auflage 2007: 654

Haimov-Kochmann R, Hochner-Celnikier D. Hot flashes revisited: pharmacological and herbal options for hot flashes management. What does the evidence tell us? Acta Obstetricia et Gynecologica Scandinavica 2005, 84: 972-979

Hanna K, Day A, O'Neill S, Patterson C, Lyons-Wall P. Does scientific evidence support the use of non-prescription supplements for treatment of acute menopausal symptoms such as hot flushes? Nutrition & Dietetics 2005, 62:4

Harbeck N, Jakesz R. St. Gallen 2007: Breast cancer treatment consensus report. Breast Care 2007, 2: 130-134

Haynes B, Dowsett M. Clinical pharmacology of selective estrogen receptor modulators. Drug & Aging 1999, 5: 323-336

Hlatky MA, Boothroyd D, Vittinghoff E, Sharp P, Whooley MA. Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy. *JAMA* 2002, 287(5): 591-597

Huntley A. The safety of black cohosh (*Actaea racemosa*, *Cimicifuga racemosa*). *Expert Opinion Drug Safety*. 2004, 3(6): 615-623

Huntley A, Ernst E. A systematic review of the safety of black cohosh. *Menopause* 2003, 10(1): 58-64

Jadad AR. JADAD Score. Available at:

[http://www.ebn.at/cms/dokumente/10089199\\_1486478/68ad7abd/Jadad-Score\\_.pdf](http://www.ebn.at/cms/dokumente/10089199_1486478/68ad7abd/Jadad-Score_.pdf)

Joy D, Joy J, Duane P. Black cohosh: a cause of abnormal postmenopausal liver function tests. *Climacteric* 2008, 11: 84-88

Kaiser WD, Martin R, Schellenberg R, Schrader E, Saller R. Cimicifuga-racemosa-Extrakt ZE 450 bei Wechseljahrsbeschwerden Praxisstudie. *Ars Medici*, 17, 2008 771-774

Kenemans P. Climacteric and postmenopause: definitions, terms and concepts. WOMAN-II website 21/02/2003, Available at: <http://www.womanlab.com/>

Kotlarczyk MP, Davis VL, Jayo MJ. Effects of black cohosh treatment on metastatic markers in the MMTV/neu model of breast cancer. *Proc Amer Assoc Cancer Res* 2006, Vol 47, Prevention research 8: Phytochemicals/Chemoprevention 2, Abstract #3926

Kretzschmar G, Nisslein T, Zierau O, Vollmer G. No estrogen-like effects of an isopropanolic extract of Rhizoma Cimicifugae racemosae on uterus and vena cava of rats after 17 day treatment. *Journal of steroid biochemistry & molecular biology* 2005, 97: 271-277

Kronenberg F, Fugh-Berman A. Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled studies. *Annals of Internal Medicine* 2002, 137 (10): 805-813

Kupperman HS, Wetchler BB, Blatt MHG. Contemporary therapy of the menopausal syndrome. *JAMA* 1959, 171: 1627-1637

Levitsky J, Alli, TA, Wisecarver J, Sorrell MF. Fulminant liver failure associated with the use of black cohosh. *Digestive Diseases and Sciences* 2005, 50(3): 538-539

Liebermann S. A review of the effectiveness of *Cimicifuga racemosa* (black cohosh) for the symptoms of menopause. *Journal of women's health* 1998, 7(5): 525-9

Liske E, Boblitz N. Kooperation Phytopharmaka: *Cimicifuga racemosa* rhizome. Kooperation Phytopharmaka 1999, Aktualisiertes Wissenschaftliches Erkenntnismaterial 1999

Low Dog T, Powell KL, Weismann SW. Critical evaluation of the safety of *Cimicifuga racemosa* in menopause symptom relief. *Menopause* 2003, 10(4): 299-313

Maartens LW, Leusink GL, Knottnerus JA, Smeets CG, Pop VJ. Climacteric complaints in the community. *Family practice* 2001, 18(2): 189-194

Mahady GB. Black Cohosh (*Actaea/Cimicifuga racemosa*) Review of the clinical data for safety and efficacy in menopausal symptoms. *Treat Endocrinol* 2005, 4(3): 177-184

Mahady GB, Fabricant D, Chadwick, LR, Dietz B. Black cohosh: an alternative therapy for menopause? *Nutr Clin Care* 2002, 5(6): 283-9.

Melchert F, Schmidt-Gollwitzer K, Machens K. Hormonsubstition (HRT) im Klimakterium. Wischnik, Kompendium Gynäkologie und Geburtshilfe 7. Erg.-Lfg. 12/04, IV-4

Menopause. Position Statement: treatment of menopause-associated vasomotor symptoms: position statement of the North American Menopause Society. Menopause 2004, 11(1): 11-33

MHRA. Black Cohosh; UK Public Assessment Report.

<http://www.mhra.gov.uk/home/groups/es-herbal/documents/websiteresources/con2024279.pdf>

MHRA. Menoherb film-coated tablets.

<http://www.mhra.gov.uk/home/groups/1-unit1/documents/websiterecources/con2032094.pdf>

Nelson H, Vesco KK, Haney E, Fu R, Nedrow A, Miller J et al. Nonhormonal therapies for menopausal hot flashes. Systemic review and meta-analysis. JAMA 2006, 295(17): 2057-2071

Ness J, Aronow WS, Beck G. Menopausal symptoms after cessation of hormone replacement therapy. Maturitas 2006, 53: 356-361

Nisbet BC, O'Connor RE. Black cohosh-induced hepatitis. Del Med Jrl 2008, 79(11): 441-444

Nißelein T, Freudenstein J. Coadministration of the aromatase inhibitor formestane and an isopropanoloc extract of black cohosh in a rat model of chemically induced mammary carcinoma. Planta Med 2007, 73: 318-322

O'Connor AM, Merel NH, Te HS, Cohen SM. A case of autoimmune hepatitis associated with the use of black cohosh. AJG 2009, Abstract 5165

Osmers R, Kraft K. Phytotherapie bei Wechseljahrsbeschwerden. Pharm. Unserer Zeit 2004, 33. Jahrgang Nr 5, 384-391

Overk CR, Yao P, Chen S, Deng S, Imai A, Main M et al. High-content screening and mechanism-based evaluation of estrogenic botanical extracts. Combinatorial Chemistry & High Throughout Screening 2008, 17:283-293

Pivonello R, Ferone D, Lombardi G, Colao A, Lamberts SW, Hofland LJ. Novel insights in dopamine receptor physiology. European Journal of Endocrinology 2007, 156: 13-21

Rand-36. RAND-36 Quality-Of-Life Questionnaire. The Finnish Medical Society Duodecim, Ann Med 2001, 33: 350-357

Rhyu M-R, Lu J, Webster DE, Fabricant DS, Farnsworth NR, Wang ZJ. Black cohosh (*Actaea racemosa*, *Cimicifuga racemosa*) behaves as a mixed competitive ligand and partial agonist at the human mu opiate receptor. J Agric Food Chem 2006, 54(26): 9852-9857

Rotem C, Kaplan B. Phyto-Female Complex for the relief of hot flushes, night sweats and quality of sleep: Randomized, controlled, double-blind pilot study. Gynecological Endocrinology 2007, 23(2):117-122

Schulz V. Wechseljahresbeschwerden: Verwirrende US-Studie stellt Wirksamkeit von Cimicifugawurzel-Extrakt infrage. Zeitschrift für Phytotherapie 2007, 28: 73-75

Shuster J. Black cohosh root? Chasteberry tree? Seizures! Hospital pharmacy 1996, 31(12): 1553-1554

van der Sluijs CP, Bensoussan A, Chang S, Baber R. A randomized placebo-controlled trial on the effectiveness of an herbal formula to alleviate menopausal vasomotor symptoms. Menopause 2009, 16(2): 336-344

Teschke R, Bahre R, Gentner A, Fuchs J, Schmidt-Taenzer W, Albrecht W. Suspected black cohosh hepatotoxicity – Challenges and pitfalls of causality assessment. *Maturitas* 2009, 1-13

Teschke R, Bahre R, Fuchs J, Wolff Albrecht. Black cohosh hepatotoxicity: quantitative causality evaluation in nine suspected cases. *Menopause* 2009, 16(5): 1-10

Teschke R, Schwarzenboeck A. Suspected hepatotoxicity by *Cimicifugae racemosae rhizoma* (black cohosh, root): critical analysis and structured causality assessment. *Phytomedicine* 2009, 16: 72-84

Thomsen M, Schmidt M. Hepatotoxicität durch *Cimicifuga Racemosa*? *Zeitschrift für Phytotherapie* 2003, 24: 11-14

Viereck V, Emons G, Wuttke W. Black cohosh: just another phytoestrogen? *Trends in endocrinology and metabolism* 2005, 16(5): 214-21

Wenpei B, Henneicke-von Zepelin HH, Wang S, Zheng S, Liu J, Zhang Z et al. Efficacy and tolerability of a medicinal product containing an isopropanolic black cohosh extract in Chinese women with menopausal symptoms: A randomized, double blind, parallel-controlled study versus tibolone. *Maturitas* 2007, 58: 31-41

Whiting PW, Clouston A, Kerlin P. Black cohosh and other herbal remedies associated with acute hepatitis. *MJA* 2002, 177: 432-435

Winterhoff H, Spengler B, Christoffel V, Butterweck V, Löhnig A. *Cimicifuga* extract BNO 1055: reduction of hot flushes and hints on antidepressant activity. *Maturitas* 2003, 44(1): 51-58

Wuttke W, Jarry H, Becker T, Schultens A, Christoffel V, Gorkow C, Seidlova-Wuttke D. Phytoöstrogene – eine Alternative zur Standardhormonersatztherapie? *Der Gynäkologe* 2002, 35: 1007-1020

Zierau O, Bodinet C, Kolba S, Wulf M, Vollmer G. Antiestrogenic activities of *Cimicifuga racemosa* extracts. *Journal of Steroid Biochemistry & Molecular Biology* 2002, 80: 125-130